PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 53, Issue , 2014, Pages 35-44

  Barbiero, Janaína K ^a   Santiago, Ronise ^a   Tonin, Fernanda S ^a   Boschen, Suelen ^a   Da Silva, Luísa Mota ^a   De Paula Werner, Maria Fernanda ^a   Da Cunha, Claudio ^a   Lima, Marcelo M S ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dopamine; Fenofibrate; MPTP; Parkinson's disease; PPAR

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; FENOFIBRATE; GLUTATHIONE PEROXIDASE; LIPID HYDROPEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; ANTILIPEMIC AGENT; GLUTATHIONE; LIPID PEROXIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; FORCED SWIM TEST; LOCOMOTION; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; TWO-WAY ACTIVE AVOIDANCE TEST; ANIMAL; COMPLICATION; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; EXPLORATORY BEHAVIOR; INTOXICATION; METABOLISM; SWIMMING; TIME; WISTAR RAT;

ANIMALS; AVOIDANCE LEARNING; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; ENCEPHALITIS; EXPLORATORY BEHAVIOR; FENOFIBRATE; GLUTATHIONE; HYPOLIPIDEMIC AGENTS; LIPID PEROXIDES; MALE; MPTP POISONING; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; SWIMMING; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84896994931     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.02.009     Document Type: Article

References (94)

1. Aarsland D., Pahlhagen S., Ballard C.G., Ehrt U., Svenningsson P. Depression in Parkinson disease - epidemiology, mechanisms and management. Nat Rev Neurol 2012, 8:35-47.
2. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975, 32:114-118.
3. Aubin N., Curet O., Deffois A., Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998, 71:1635-1642.
4. Barbiero J.K., Santiago R.M., Lima M.M.S., Ariza D., Morais L.H., Andreatini R., et al. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res 2012, 216:186-192.
5. Bartels A.L., Leenders K.L. Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex 2009, 45:915-921.
6. Beltowski J., Wojcicka G., Mydlarczyk M., Jamroz A. The effect of peroxisome proliferator-activated receptors α (PPARα) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 2002, 53:463-475.
7. Bharath S., Hsu M., Kaur D., Rajagopalan S., Andersen J.K. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002, 64:1037-1048.
8. Bhateja D.K., Dhull D.K., Gill A., Sidhu A., Sharma S., Reddy B.V., et al. Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. Eur J Pharmacol 2012, 674:33-43.
9. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., et al. PPAR: a new pharmacological target for neuroprotection in stroke and neuro-degenerative diseases. Biochem Soc Trans 2006, 34:1341-1346.
10. Bright J.J., Kanakasabai S., Chearwae W., Chakraborty S. PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res 2008, 2008:1-12.
11. Cannon J.R., Greenamyre J.T. Neurotoxic in vivo models of Parkinson's disease: recent advances. Prog Brain Res 2010, 184:17-33.
12. Capitelli C., Sereniki A., Lima M.M., Reksidler A.B., Tufik S., Vital M.A. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008, 594:101-108.
13. Carta A.R., Pisanu A. Modulating microglia activity with PPAR- agonists: a promising therapy for Parkinson's disease?. Neurotox Res 2012, 2:112-123.
14. Chen C.M., Yin M.C., Hsu C.C., Liu T.C. Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition 2007, 23:589-597.
15. Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 2007, 24:1119-1131.
16. Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-α agonist WY14643. Free Radic Biol Med 2006, 41:579-589.
17. Costa A.P.R., Vieira C., Bohner L.O.L., Silva C.F., Santos E.C.S., De Lima T.C.M., et al. A proposal for refining the forced swim test in Swiss mice. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:150-155.
18. Da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 2001, 124:9-18.
19. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
20. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004, 88:494-501.
21. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., et al. Peroxysome proliferator-activated receptor alpha negatively regulates the inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem 1999, 274:32048-32054.
22. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 2000, 275:36703-36707.
23. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
24. Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 2013, 275:36703-36707.
25. Diep Q.N., Benkiran K., Amiri F., Jeffrey S., Cohn J.S., Endemann D., et al. PPARa activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004, 36:295-304.
26. Dolga A.M., Culmsee C., Lau L., Winter Y., Oertel W.H., Luiten P.G.M., et al. Statins - increasing or reducing the risk of Parkinson's disease?. Exp Neurol 2010, 228:1-4.
27. Dorado-Martinez C., Paredes-Carbajal C., Mascher D., Borgonio-Perez G., Rivas-Arancibia S. Effects of different ozone doses on memory, motor activity and lipid peroxidation levels, in rats. Int J Neurosci 2001, 108:149-161.
28. Drew P.D., Xu J., Storer P.D., Chavis J.A., Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 2006, 49:183-189.
29. Fredriksson A., Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neural Transm Park Dis Dement Sect 1994, 7:123-132.
30. Gao R., Yuan Z., Zhao Z., Gao X. Mechanism of pyrogallol autoxidation and determination of superoxide dismutase enzyme activity. Bioelectrochem Bioenerg 1998, 45:41-45.
31. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H.E., Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 2009, 29:13543-13556.
32. Greenlund L.J., Deckwerth T.L., Johnson E.M. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995, 14:303-315.
33. Haavik J., Toska K. Tyrosine hydroxylase and Parkinson's disease. Mol Neurobiol 1998, 16:285-309.
34. Haleagrahara N., Ponnusamy K. Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawley rats. J Toxicol Sci 2010, 35:41-47.
35. Heikkila R.E., Sonsalla P.K. The MPTP-treated mouse as a model of parkinsonism: how good is it?. Neurochem Int 1992, 20:299S-303S.
36. Heller A., Won L., Bubula N., et al. Long-chain fatty acids increase cellular dopamine in an immortalized cell line (MN9D) derived from mouse mesencephalon. Neurosci Lett 2005, 376:35-39.
37. Heneka M.T., Landreth G.E. PPARs in the brain. Biochim Biophys Acta 2007, 1771:1031-1045.
38. Hill M.R., Clarke S., Rodgers K., Thornhill B., Peters J.M., Gonzalez F.J., et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor. Infect Immun 1999, 67:3488-3493.
39. Houseknecht K.L., Cole B.M., Steele P.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002, 22:1-23.
40. +-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress. Naunyn Schmiedeberg's Arch Pharmacol 2011, 384:157-167.
41. Hunter R.L., e Bing G. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr Neuropharmacol 2007, 5:35-46.
42. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001, 50:3-11.
43. Jiang Z., Hunt J.V., Wolf S.P. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem 1992, 202:384-389.
44. Kainu T., Wikstrom A.C., Gustafsson J.A., Pelto-Huikko M. Localization of the peroxisome proliferator-activated receptor in the brain. NeuroReport 1994, 20:2481-2485.
45. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci 1993, 90:2160-2164.
46. Kish S.J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985, 58:343-346.
47. Kreisler A., Gelé P., Wiart J.F., Lhermitte M., Destée A., Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 2007, 1135:77-84.
48. Kreisler A., Duhamel A., Vanbesien-mailliot C., Destée A., Bordet R. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease. Behav Pharmacol 2010, 21:194-205.
49. Kumar P., Kaundal R.K., More S., Sharma S.S. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav Brain Res 2009, 197. [398-40].
50. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 2004, 18:717-719.
51. Leentjens A.F. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Neuropsychopharmacology 2011, 71:273-278.
52. Lima M.M.S., Reksidler A.B., Zanata S., Machado H.B., Tufik S., Vital M.A.B.F. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006, 1101:117-125.
53. Litteljohn D., Mangano E.N., Hayley S. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur J Neurosci 2008, 28:707-716.
54. Litteljohn D., Mangano E., Shukla N., Hayley S. Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience 2009, 16:1894-1906.
55. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009, 89:277-287.
56. Marklund S., Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974, 3:469-474.
57. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
58. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
59. Miyazaki T., Shimada K., Miyauchi K., Kume A., Tanimoto K., Kiyanagi T., et al. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis 2010, 9:122.
60. Moreno S., Farioli-Vecchioli S., Cerù M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neurosciences 2003, 123:131-145.
61. Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., Kamatani N. Inhibition of NF-kappa B signaling by fenofibrate, a peroxisome pro-liferator activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:323-330.
62. Pankova N.B., Vetrile L.A., Basharova L.A., Krupina N.A., Khlebnikova N.N., Rodina V.I., et al. Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters). Neurosci Behav Physiol 2004, 34:131-138.
63. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Academic Press, San Diego. 5th ed.
64. Perry J.C., Da Cunha C., Anselmo-Franci J., Andreatini R., Miyoshi E., Tufik S., et al. Behavioural and neurochemical effects os phosphatidylserine in MPTP lesion of the substantia nigra in rats. Eur J Pharmacol 2004, 484:225-233.
65. Perry J.C., Hipplide D., Tufik S., Martins R., Da Cunha C., Andreatini R., et al. Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies. Exp Neurol 2005, 195:322-329.
66. Phani S., Loike J.D., Przedborski S. Neurodegeneration and Inflammation in Parkinson's disease. Parkinsonism Relat Disord 2012, 1:S207-S209.
67. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioral despair in rats, a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
68. Poynter M.E., Daynes R.A. Age-associated alterations in splenic iNOS regulation: influence of constitutively expressed IFN-gamma and correction following supplementation with PPAR alpha activators or vitamin E. Cell Immunol 1999, 195:127-136.
69. Rajeswari A. Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur Rev Med Pharmacol Sci 2006, 10:157-161.
70. Rajeswari A., Sabesan M. Neuropathological changes induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in male Swiss albino mice. Toxicol Ind Health 2008, 24:189-194.
71. Reksidler A.B., Lima M.M.S., Zanata S.M., Machado H.B., Da Cunha C., Andreatini R., et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007, 560:163-175.
72. Reneric J.P., Bouvard M., Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 2002, 136:521-532.
73. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989, 52:515-520.
74. Rivas-Arancibia S., Dorado-Martinez C., Borgonio-Perez G., Hiriart-Urdanivia M., Verdugo-Diaz L., Duran-Vazquez A., et al. Effects of taurine on ozone-induced memory deficits and lipid peroxidation levels in brains of young, mature, and old rats. Environ Res 2000, 82:7-17.
75. Rozas G., Liste I., Guerra M.J., Labandeira-Garcia J.L. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 1998, 245:151-154.
76. Sankar S.R., Manivasagam T., Krishnamurti A., Ramanathan M. The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice. an analysis of behavioral and biochemical variables. Cell Mol Biol 2007, 12:473-481.
77. Santiago R.M., Barbiero J.K., Lima M.M.S., Dombrowski P.A., Andreatini R., Vital M.A.B.F. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
78. Schrag A. Psychiatric aspects of Parkinson's disease - an update. J Neurol 2004, 251:795-804.
79. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
80. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968, 1:192-205.
81. Sharma A., Kaur P., Kumar V., Gill K.D. Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol 2007, 53:48-55.
82. Solla P., Cannas A., Floris G.L., Orofino G., Costantino E., Boi A., et al. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1009-1013.
83. Stéphanie P., Alice G., Sylvie B., Zuhal G., Caroline P.A., Sylvie C. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease. Exp Toxicol Pathol 2013, 65:689-694.
84. Sung B., Park S., Yu B.P., Chung H.Y. Modulation of PPAR in aging, inflammation and calorie restriction. J Gerontol A Biol Sci Med Sci 2004, 59:997-1006.
85. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin Ferreira E., Da Cunha e C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
86. Tanaka T., Kohno H., Yoshitani S., Okumura A., Murakami A., Hosokawa M. Ligands for peroxisome proliferator activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001, 61:2424-2428.
87. Thiffault C., Aumont N., Quirion R., Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 1995, 65:2725-2733.
88. Tillerson J.L., Caudle W.M., Reverón M.E., Reverón M.E., Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 2002, 178:80-90.
89. Vuckovic M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyr-idine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008, 32:319-327.
90. Wang G., Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res 2011, 70:230-237.
91. Wayman N.S., Hattori Y., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Pisano B., et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarction size. FASEB 2002, 16:1027-1040.
92. Worth P.F. How to treat Parkinson's disease in 2013. Clin Med 2013, 13:93-96.
93. Xing B., Xin T., Hunter R.L., Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J Neuroinflammation 2008, 5:4.
94. Zhang F., Liu F., Yah M., Huoyan J., Hu L., Li X., et al. Peroxisome proliferator-activated receptor- agonists suppress iNOS expression induced by LPS in rat primary Schwann cells. J Neuroimmunol 2010, 218:36-47.